 JanOne Inc. NASDAQ: JAN, a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build a world-class team of biopharma experts with the addition of Douglas Flanagan, PhD as the companys chief formulation advisor. Dr. Flanagan will work directly with CoreRX, JanOnes manufacturing partner to ensure the integrity of TV1001SR, the companys clinical candidate for treating Peripheral Artery Disease PAD expected soon to enter phase 2 trials. He will also play an integral role for the potential identification and advancement of other clinical candidates to treat pain as the company hopes to broaden its pipeline in the near future. 